A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coronary Intervention

Trial Profile

A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coronary Intervention

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms PLATIDE-PCI
  • Most Recent Events

    • 03 Jan 2017 Planned End Date changed from 1 May 2017 to 1 Apr 2018.
    • 03 Jan 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Mar 2018.
    • 03 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top